PO.MCB03.02 · 分子与细胞生物学

通过将活性与药物靶点邻近性关联来验证上游激酶预测

Validating upstream kinase predictions by linking activity to drug target proximity

海报缩略图:通过将活性与药物靶点邻近性关联来验证上游激酶预测
编号 3321 展板 28 时间 4/20 02:00–05:00 区域 Section 24 主讲 Gitanjali Dharmadhikari
分会场 RTK-ERBB-PI3K and New Targets in Therapeutic Resistance
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Dóra Schuller, Gitanjali Dharmadhikari, Monique Mommersteeg, Liesbeth Houkes, Simar Pal Singh, Rik de Wijn

PamGene International B.V., 's-Hertogenbosch, Netherlands

摘要 Abstract

中文摘要
引言:持续的细胞信号传导是肿瘤生长的标志之一。激酶信号传导的失调可通过肽微阵列或磷酸化蛋白质组学等方法进行研究。为此,从磷酸化特征预测激酶是一项关键而复杂的工作。我们研究的目的是验证激酶预测的生物学相关性,我们通过将激酶活性谱与来自癌症药物敏感性基因组学(GDSC)的敏感性数据整合来进行评估。一个基本的敏感性机制涉及抑制药物靶激酶及其下游存活通路的活性。我们可以通过网络分析检验这一机制,假设在敏感细胞中活性激酶和药物靶点的信号网络显示出高连接性,这应反映激酶预测的生物学相关性。 方法:通过KinomePro平台(PamGene International B.V.)对11个B细胞淋巴瘤细胞系进行丝氨酸/苏氨酸激酶(STK)活性分析。将对多种药物普遍敏感(IC50 < 1 μm)的10个细胞系与一个相对耐药的对照系(对较少数量药物显示敏感性)进行比较,预测激酶。使用STRING蛋白-蛋白相互作用数据库和奖励收集斯坦纳森林(Prize-Collecting Steiner Forest)算法,从顶级激酶和细胞最敏感药物的靶激酶生成细胞系特异性网络。 结果:为量化激酶和药物靶点的信号邻近性,我们开发了网络连接性评分。对于每个细胞系,我们使用每个激酶与药物靶点之间最短路径的中位数计算网络连接性。然后针对50个随机网络的参考集(使用原始药物靶点和随机化激酶数据生成)检验其统计学显著性。根据预测算法中使用的参数,10个B细胞淋巴瘤细胞系中有5个的激酶预测产生了显著的网络连接性评分(p < 0.07)。这些结果证明了该方法在识别预测算法最佳参数设置方面的效用。 结论:我们开发了一种验证方法,用于验证在细胞环境中获得的磷酸化特征所得激酶预测的生物学相关性。未来的工作将集中于应用该方法,通过评估和优化激酶预测方法的性能及其潜在偏差,来改进对激酶在信号转导中作用的研究。
查看英文原文 English abstract
Introduction: Sustained cell signaling is one of the hallmarks of tumor growth. Deregulation of kinase signaling can be studied by methods such as peptide microarrays or phospho-proteomics. For this, the prediction of kinases from phosphorylation signatures is a critical and complex. The aim of our study is to validate the biological relevance of kinase predictions, which we evaluate by the integration of kinase activity profiles with sensitivity data from the Genomics of Drug Sensitivity in Cancer (GDSC). A fundamental sensitivity mechanism involves repressing the activity of the drug's target kinase and its downstream survival pathways. We can test this mechanism through network analysis, hypothesizing that the signaling networks of active kinases and drug targets show high connectivity in sensitive cells, that should reflect the biological relevance of the kinase predictions. Methods : Serine/Threonine Kinase (STK) activity profiling of 11 B-cell lymphoma cell lines was performed via the KinomePro platform (PamGene International B.V.). Kinases were predicted for 10 cell lines generally sensitive to multiple drugs (IC 50 < 1 µm) compared to one relatively resistant control line (showing sensitivity to a smaller number of drugs). Cell line specific networks were generated from the top kinases and the target kinases of drugs the cells were most sensitive to, using the STRING protein-protein interaction database and Prize-Collecting Steiner Forest algorithm. Results: To quantify signaling proximity of kinases and drug targets, we developed the network connectivity score. For each cell line, we calculated network connectivity using the median of the shortest paths between each kinase and drug target. This was then tested for statistical significance against a reference set of 50 random networks, generated using the original drug targets and randomized kinase data. Kinase predictions for 5 out of 10 B-cell lymphoma cell lines resulted in significant network connectivity score (p < 0.07), depending on the parameters used in the prediction algorithm. These results demonstrate the method's utility to identify optimal parameter settings for the prediction algorithm. Conclusion: We developed a validation method for the biological relevance of kinase predictions from phosphorylation signatures obtained in a cellular context. Future work will focus on applying this method to improve studies of the role of kinases in signal transduction by evaluating and optimizing the performance of kinase prediction methods and their potential biases.
利益披露 Disclosure
D. Schuller, PamGene International B.V. Employment. G. Dharmadhikari, PamGene International B.V. Employment. M. Mommersteeg, PamGene International B.V. Employment. L. Houkes, PamGene International B.V. Employment. S. P. Singh, PamGene International B.V. Employment. R. de Wijn, PamGene International B.V. Employment.

← 返回 AACR 2026 检索